NexACT works as an anti-microbial preservative, says Apricus Bio

Apricus Bio’s NexACT drug delivery technology has qualified as an anti-microbial preservative, according to results from a US Pharmacopeia Preservative Efficacy Test (USP PET).

The results show the US drug delivery specialist’s NexACT technology is capable of killing over 23 different strains of bacteria, fungus and mold, exceeding all requirements for passing the USP PET.

Bassam Damaj, president and CEO of Apricus Bio, commented: “The safety of NexACT has been tested extensively in over 4,500 patients to date, with excellent results.” ​This places the technology in good stead to compete with other commonly used preservatives, such as parabens.

“The ability of NexACT to function as a preservative opens up new partnering opportunities with pharmaceutical and cosmetic developers,”​ he added.

Earlier this year, Apricus Bio received $2.7m (€2.0m) in development funding for NexACT from two US investors, and have since signed a distribution deal with Cosmo Bio to market products based on NexACT technology in Japan.

Related topics Ingredients Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Webinars

Headlines